Crisco

CRISPR Therapeutics is a leading gene editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. The company's pipeline includes programs in hemoglobinopathies, oncology, regenerative medicine, and rare diseases. Its lead product, Casgevy (exagamglogene autotemcel), developed in partnership with Vertex Pharmaceuticals, is the first CRISPR-based therapy to receive regulatory approval for sickle cell disease and beta thalassemia. CRISPR Therapeutics is headquartered in Zug, Switzerland, with significant R&D operations in Cambridge, Massachusetts. The company continues to expand its platform into in vivo gene editing and chronic diseases like diabetes and cardiovascular conditions.